Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
NeuroSense Therapeutics Ltd. Warrant (NRSNW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: NRSNW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -88.45% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 1.6 | 52 Weeks Range 0.10 - 1.06 | Updated Date 06/21/2025 |
52 Weeks Range 0.10 - 1.06 | Updated Date 06/21/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.94 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -159.5% | Return on Equity (TTM) -2478.16% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 11925007 |
Shares Outstanding - | Shares Floating 11925007 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
NeuroSense Therapeutics Ltd. Warrant
Company Overview
History and Background
NeuroSense Therapeutics Ltd. is a clinical-stage biopharmaceutical company focused on discovering and developing treatments for neurodegenerative diseases. The warrant is a security that gives the holder the right to purchase shares of the company's stock at a specified price within a certain time period. The company was founded to address unmet needs in neurodegenerative disease treatment.
Core Business Areas
- Drug Development: Developing therapeutics targeting neurodegenerative diseases like Amyotrophic Lateral Sclerosis (ALS), Alzheimer's Disease and Parkinson's Disease. The company's primary focus is on its lead compound, PrimeC, for ALS.
Leadership and Structure
NeuroSense's leadership team consists of experienced professionals in drug development, clinical research, and business strategy. The company operates with a structure focused on efficient research, clinical trials, and potential commercialization.
Top Products and Market Share
Key Offerings
- PrimeC: PrimeC is NeuroSense's lead drug candidate for ALS. It is a combination drug being developed to address multiple pathogenic mechanisms in ALS. Market share data is not yet available as the drug is still in clinical development. Competitors in ALS treatment include: Relyvrio (AMX0035), Radicava (edaravone), and riluzole.
Market Dynamics
Industry Overview
The neurodegenerative disease treatment market is large and growing, driven by aging populations and increasing prevalence of diseases like ALS, Alzheimer's, and Parkinson's. The market is characterized by high unmet need and intense competition.
Positioning
NeuroSense is a clinical-stage company aiming to differentiate itself with PrimeC, which targets multiple pathways in ALS. Its competitive advantage hinges on the clinical success and potential efficacy of PrimeC.
Total Addressable Market (TAM)
The TAM for neurodegenerative disease treatments is estimated in the billions of dollars. NeuroSense aims to capture a significant portion of the ALS market with PrimeC, if approved.
Upturn SWOT Analysis
Strengths
- Novel drug candidate (PrimeC) targeting multiple mechanisms in ALS
- Experienced management team
- Potential to address high unmet need in ALS treatment
Weaknesses
- Clinical-stage company with no currently approved products
- High risk of clinical trial failure
- Limited financial resources compared to larger pharmaceutical companies
Opportunities
- Positive clinical trial results for PrimeC
- Partnerships with larger pharmaceutical companies
- Expansion into other neurodegenerative diseases
Threats
- Clinical trial failure
- Competition from other companies developing ALS treatments
- Regulatory hurdles
- Funding constraints
Competitors and Market Share
Key Competitors
- AMKR
- IONS
- ITCI
Competitive Landscape
NeuroSense faces intense competition from established pharmaceutical companies and other biotechs in the neurodegenerative disease space. Its competitive advantage depends on the unique mechanism of action and clinical efficacy of PrimeC.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily reflected in the advancement of PrimeC through clinical trials.
Future Projections: Future growth depends on the successful completion of clinical trials and potential approval and commercialization of PrimeC. Analyst estimates are unavailable as the company is lightly covered.
Recent Initiatives: Recent initiatives include advancing PrimeC through ongoing clinical trials and exploring potential partnerships.
Summary
NeuroSense Therapeutics is a clinical-stage biopharmaceutical company with its lead drug candidate, PrimeC, focusing on ALS. The company's success is highly dependent on the outcome of PrimeC's clinical trials. Key strengths include its experienced management and unique drug candidate. However, it also faces weaknesses being a clinical stage company and threats from competitors and regulatory hurdles, as well as funding challenges.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment in NeuroSense Therapeutics Ltd. Warrant involves significant risks.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About NeuroSense Therapeutics Ltd. Warrant
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-12-09 | Co-Founder, CEO & Director Mr. Alon Ben-Noon | ||
Sector Healthcare | Industry Biotechnology | Full time employees 17 | Website https://www.neurosense-tx.com |
Full time employees 17 | Website https://www.neurosense-tx.com | ||
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.